June 15, 2020
Fresenius Medical Care expands production at St. Wendel plant in response to higher demand caused by COVID-19 pandemic
Fresenius Medical Care, the world’s leading provider of dialysis products and services, has started a new production line for dialysis fluids at its St. Wendel, Germany, plant. The new line for so-called “CiCa solutions” – citrate anticoagulants, which prevent clotting of the blood – is the plant’s fifth production line for dialysis fluids used in the treatment of acute and chronic kidney disease. These and other dialysis products manufactured by the company in St. Wendel are shipped to healthcare facilities around the world.
Work on the new line was accelerated due to the coronavirus pandemic, enabling the company to put it into operation several months ahead of schedule. Severe COVID-19 cases often cause acute kidney failure, which has significantly increased worldwide demand for the solutions needed to conduct acute dialysis. By speeding the line’s completion, Fresenius Medical Care is helping to ensure the continued availability of these life-sustaining medicinal products.
“As one of the world’s most important manufacturing facilities for dialysis products, we are facing particular challenges from the pandemic,” said Plant Manager Gerhard Breith. “I am very proud that thanks to the extraordinary commitment of everyone involved, and the unmatched team spirit of our employees, we were able to complete this production line well ahead of schedule.”
Fresenius Medical Care’s St. Wendel plant, which went into operation in 1974, is one of the world’s largest production facilities for dialysis products and is also the development center for new products and production processes adopted by other company plants. Fresenius Medical Care has about 2,000 employees in St. Wendel.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.